Usefulness of Myocardial Deformation Imaging for Trastuzumab-induced Cardiotoxicity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-07-31

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Trastuzumab prolongs survival in patients with human epidermal growth factor receptor type 2-positive breast cancer. Sequential left ventricular (LV) ejection fraction (EF) assessment has been mandated to detect myocardial dysfunction because of the risk of heart failure with this treatment. Myocardial deformation imaging is a sensitive means of detecting LV dysfunction, but this technique has not been evaluated in patients treated with trastuzumab. The aim of this study was to investigate whether changes in tissue deformation, assessed by myocardial strain and strain rate (SR), are able to identify LV dysfunction earlier than conventional echocardiographic measures in patients treated with trastuzumab.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients

NCT04790266

Cardiotoxicity

COMPLETED

NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity

NCT06340516

Cardiotoxicity Breast Cancer Treatment Side Effects

RECRUITING NA

Comparison Between Myocardial Tomoscintigraphies Using a Semiconductor Camera or a Conventional Camera

NCT02861235

Myocardial Infarction Ischemia

COMPLETED NA

Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study

NCT05851053

Neoplasm, Breast Heart Failure Cardiotoxicity +1 more

RECRUITING

Early Detection of Imaging-derived Subclinical Cardiac Injuries

NCT03575650

Cardiovascular Diseases

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will prospectively evaluate whether changes in tissue deformation, assessed by myocardial strain and strain rate (SR) and identify possibility of early detection of LV dysfunction in patients treated with trastuzumab.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Left Ventricular Function Systolic Dysfunction Cardiotoxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HER2(+) breast cancer, anticipating Trastuzumab therapy

Exclusion Criteria

* Refusal to informed consent
* Congenital heart disease
* Significant arrhythmia in EKG
* Regional wall motion abnormality (+) in echocardiography
* Poor sonic window

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No